PATENT CLAIM ANALYSIS

Application Number: 16076479
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2019-02
Patent Classification: ["424", "136100"]

Abstract:
The present invention relates to engineered cells, engineered chimaeric antigen ligands (CALs), novel uses of multi-specific binding agents for bridging cells, and methods of therapy. The invention also provides variation-matched engineered cells.

Claim (Index 98):
The method of  claim 96 , wherein the immune cell is a Tumour-Infiltrating Lymphocyte (TIL) and/or the bridging agent is a bi- or tri-specific antigen binding fragment comprising two or three scFv binding sites, wherein the cancer is a solid tumour or melanoma.

Metadata:
- Claim Count in Document: 53.0
- Percentile: 96.0
- Lexical Diversity: 1.34483
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15866222', '15934770', '15105074', '15637734', '15106783']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.738832171557852
- 35 USC 102 Novelty (BERT): 0.5216402828757238
- Combined Prediction Score: 0.7171129826896392
- Mean Citation Score: 319.32395
- Max Citation Score: 322.89294
- Similarity Product: 209.4034316913236

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test